Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- New year's Messages
January 3, 2005
- Chuikyo's Role Should Be Restricted to Price Setting: Council
January 3, 2005
- PhRMA to Actively Discuss Healthcare Reform
January 3, 2005
- NHI Listing of Epzicom, Lexiva Recommended
January 3, 2005
- For Innovation-Friendly and Patient-Oriented Healthcare
January 3, 2005
- Korosho Draft Budget Increases 3.1% to \20.8 Trillion
January 3, 2005
- Looking at the Year Ahead
January 3, 2005
- NEW PRODUCTS
January 3, 2005
- New year's Commentary
January 3, 2005
- Challenges Ahead for Everyone
January 3, 2005
- Blopress Passes Mevalotin as Top-selling Drug in 1st Half
January 3, 2005
- AstraZeneca Aims at Gaining 20% of Statin Market by Crestor: Dr Kato
January 3, 2005
- Tanabe Completes Enrollment of 1st 5,000 Remicade Users
January 3, 2005
- Sales of Kyowa Hakko's Allelock Expected to Rise 35% in 2nd Half
January 3, 2005
- JSGM to Introduce GE Information System on Full Scale in April
December 27, 2004
- REGULATORY NEWS IN BRIEF
December 27, 2004
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 27, 2004
- NEW PRODUCTS
December 27, 2004
- Website News
December 27, 2004
- Base Sequences Predict Iressa Adverse Reactions: IMSUT Group
December 27, 2004
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…